טוען...

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses. METHODS: Enrolled patients had ALK...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Thorac Oncol
Main Authors: Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, Petris, Luigi De, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6886236/
https://ncbi.nlm.nih.gov/pubmed/28689043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.06.070
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!